Decreased tear levels of neuromediators are linked to impaired lacrimal function

Article

Decreased tear levels of neuropeptide Y (NPY) and calcitonin gene?related peptide (CGRP) are linked to damaged tear function.

Decreased tear levels of neuropeptide Y (NPY) and calcitonin gene–related peptide (CGRP) are linked to damaged tear function, according to a paper published in the Archives of Ophthalmology.

Dr Alessandro Lambiase et al., Department of Ophthalmology, Campus Bio-Medico, University of Rome, Italy, studied 19 patients with dry eye disease and 12 healthy participants. All patients were examined by slitlamp examination, Schirmer testing, fluorescein staining, and tear film break-up time. Tear samples were gathered, along with the grading of dry eye severity. Substance P, calcitonin gene–related peptide (CGRP), neuropeptide Y (NPY), vasoactive intestinal peptide, and nerve growth factor (NGF) concentrations were assessed by enzyme-linked immunoassay and linked to the clinical results.

It was found that nerve growth factor tear levels were significantly higher in patients with dry eye disease. CGRP and NPY concentrations were significantly reduced compared to healthy participants.

The severity of dry eye was directly linked to NGF and inversely correlated with CGRP and NPY tear levels. Conjunctival hyperemia and fluorescein staining results were directly correlated with nerve growth tear factor.

CGRP was directly linked to Schirmer test results and NPY was inversely linked to tear film break-up time. NGF tear levels strongly correlate with corneal epithelial damage. The study suggests the importance of NPY, CRGP and NGF as markers of dry eye severity.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.